Anti-HCV reactive blood donors: Clinical and epidemiological factors associated with false-reactive results

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 11, 2008, Pages 1071-1076

  Narciso Schiavon, Janaína L ^a,b   Schiavon, Leonardo L ^a   Carvalho Filho, Roberto J ^a   Cardoso, Jaqueline R ^a   Freire, Fernanda C F ^a   Sampaio, Juliana P ^a   Bordin, José O ^a   Soares, Maria Angélica ^a   Silva, Antonio Eduardo B ^a   Ferraz, Maria Lucia G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anti hepatitis C virus; Blood donors; False reactive; Hepatitis C

Indexed keywords

HEPATITIS C VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ALCOHOL ABUSE; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; DIAGNOSTIC ERROR; FEMALE; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; TERTIARY HEALTH CARE; VIRUS REACTIVATION;

ADULT; BLOOD DONORS; EPIDEMIOLOGIC METHODS; FALSE POSITIVE REACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; YOUNG ADULT;

EID: 55349117127     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328303e1d6     Document Type: Article

References (48)

1. Alter MJ. Hepatitis C: a sleeping giant? Am J Med 1991; 91:1123-1158.
2. National Hepatitis C Prevention Strategy Hepatitis C Infection in the United States, (homepage on the Internet). Atlanta: Centres for Disease Control; c2001 (updated 2006 Dec 8; cited 2007 Nov 17). Available from: http://www.cdc.gov/Ncidod/diseases/hepatitis/c/plan/HCV_infection.htm.
3. Kupek EJ. Residual transfusion risk for hepatitis B and C in southern Brazil, 1991-99. J Viral Hepat 2001; 8:78-82.
4. World Health Organization. Hepatitis C: global prevalence. Weekly Epidemiol Rec 1997; 72:341-344.
5. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17:1730-1733.
6. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
7. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill 2005; 10:17-19.
8. Akhtar S, Younus M, Adil S, Jafri SH, Hassan F. Hepatitis C virus infection in asymptomatic blood donors in Karachi, Pakistan. J Viral Hepat 2004; 11:527-535.
9. Andrade AF, Oliveira-Silva M, Silva SG, Motta U, Bonvicino CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem Inst Oswaldo Cruz 2006; 101:673-676.
10. Gonçales FL Jr, Boccato RSBS, Pedro RJ, Papaiordanou PMO, Souza CA, Goncales NSL, et al. [Prevalências do HBsAg, do anti-HBc e do anti-HCV na população de candidates a doadores de sangue do Hemocentro-Campinas]. Rev Inst Med Trop São Paulo 1993; 35:45-51.
11. Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008; 80:53-57.
12. Sakugawa H, Nakasone H, Nakayoshi T, Kinjo F, Saito A, Yakabi S, et al. High proportion of false positive reactions among donors with anti-HCV antibodies in a low prevalence area. J Med Virol 1995; 46:334-338.
13. McLindon JP, Paver WK, Babbs C, Yates AD, McMahon RF, Love EM, et al. Hepatitis C-related chronic liver disease among asymptomatic blood donors in the north west of England. J Infect 1995; 30:253-259.
14. Bar-Shany S, Green MS, Shinar E. False positive tests for anti-hepatitis C antibodies and the problem of notifying blood donors, Int J Epidemiol 1996; 25:674-678.
15. Ownby HE, Korelitz JJ, Busch MP, Williams AE, Kleinman SH, Gilcher RO, et al. Loss of volunteer blood donors because of unconfirmed enzyme immunoassay screening results. Retrovirus Epidemiology Donor Study. Transfusion 1997; 37:199-205.
16. Kiely P, Wilson D. Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management. Transfusion 2000; 40:580-584.
17. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27:1700-1702.
18. Dhumeaux D, Doffoel M, Galmiche JR A French consensus conference on hepatitis C: screening and treatment. J Hepatol 1997; 27:941-944.
19. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46:2050-2068.
20. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 (3 Suppl 1):S34-S38.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30 (Suppl 1):S42-S47.
22. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285:2486-2497.
23. Younossi Z, McHutchison J. Serological tests for HCV infection. Viral Hepat Rev 1996; 2:161-173.
24. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68:15-18.
25. Alter MJ, Kuhnert WL, Finelli L Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1-13.
26. Kim YS, Lee HS, Ahn YO. Factors associated with positive predictability of the anti-HCV ELISA method with confirmatory RT-PCR. J Korean Med Sci 1999; 14:629-634.
27. Souto FJD, Ribeiro LC, Perazolo GF, Fortes HM, Saldanha AA. [Immunoblot as a supplemental test to detect antibodies to hepatitis C virus in blood donors]. Rev Soc Bras Med Trop 2002; 35:69-71.
28. Gonçales NSL. [Hepatitis C infection in blood donors: diagnosis of hepatitis C virus by a reverse transcriptase nested polymerase chain reaction (RT-PCR) and correlation with the enzyme immunoassay (EIA) and recombinant protein immunoblot assay (RIBA) status]. Rev Soc Bras Med Tropical 1999; 32:309-311.
29. Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992; 32:805-813.
30. Roome AJ, Hadler JL, Thomas AL, Migicovsky B, Roth R, Boraz M, et al. Hepatitis C virus infection among firefighters, emergency medical technicians, and paramedics-selected locations, United States, 1991-2000. MMWR Morb Mortal Wkly Rep 2000; 49:660-665.
31. Tynell E, Norda R, Ekermo B, Sanner M, Andersson S, Bjorkman A. False-reactive microbiologic screening test results in Swedish blood donors-how big is the problem? A survey among blood centres and deferred donors. Transfusion 2007; 47:80-89.
32. Mathei C, Buntinx F, Van Damme P. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? J Infect Dis 2001; 184:659-660.
33. Thakral B, Marwaha N, Chawla YK, Saluja K, Sharma A, Sharma RR, et al. Prevalence & significance of hepatitis C virus (HCV) seroreactivity in blood donors. Indian J Med Res 2006; 124:431-438.
34. Thomas DL, Rich JD, Schuman P, Smith DK, Astemborski JA, Nolt KR, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 2001; 183:973-976.
35. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36:242-252.
36. Nalpas B, Thiers V, Pol S, Driss F, Thepot V, Berthelot P, Brechot C. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992; 14:381-384.
37. Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse: the major route of hepatitis C virus transmission among alcohol-dependent individuals? Scand J Gastroenterol 1993; 28:714-718.
38. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95:3529-3536.
39. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV co-infection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64:350-355.
40. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int 2003; 23:12-18.
41. Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H. Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2003; 48:1786-1792.
42. MacKenzie WR, Davis JP, Peterson DE, Hibbard AJ, Becker G, Zarvan BS. Multiple false-positive serologic tests for HIV, HTLV-1, and hepatitis C following influenza vaccination, 1991. J Am Med Assoc 1992; 268:1015-1017.
43. Agha S, El-Mashad N, El-Malky M, El-Shony H, El-Sherif MZ, El-Hasan MA, et al. Prevalence of low positive anti-HCV antibodies in blood donors: schistosoma mansoni co-infection and possible role of autoantibodies. Microbiol Immunol 2006; 50:447-452.
44. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756-762.
45. Prati D. Transmission of hepatitis C virus by Wood transfusions and other medical procedures: a global review. J Hepatol 2006; 45:607-616.
46. Blood Donation Eligibility Guidelines. (Homepage on the Internet). Washington: The American National Red Cross (updated 2007 May 24; cited 2008 Jan 4). Available from: http://www.redcross.org/services/biomed/0,1082,0_557_,00. html#blotra.
47. Gonçales FL Jr. Prospective clinical and epidemiological evaluation of anti-HCV reagent blood donors cadidates. Rev Soc Bras Med Trop 1998; 32:315-317.
48. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123:1367-1384.